Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AstraZeneca said its liver cancer treatment had received orphan drug designation from the US Food and Drug Administration.
Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine for the treatment of hepatocellular carcinoma, the most common type of liver cancer were currently in phase III trial testing.
The FDA grants orphan drug designation (ODD) status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.
In a separate statement, the company said the US Food and Drug administration had approved its application for a cancer drug Lynparza.
A review date was set for the second quarter of 2020.